Clinical and histopathological characteristics have limited prognostic value for children with anaplastic large cell lymphoma (ALCL). We evaluated the presence, 
Introduction
Anaplastic large cell lymphoma (ALCL) accounts for 10-15% of pediatric and adolescent non-Hodgkin lymphomas 1 . The relapse rate of children and adolescents with ALCL still reaches 30% even after use of current, intensive short-pulse chemotherapy strategies [2] [3] [4] [5] [6] . Analyses of cumulative data from European national studies identified the clinically based poor prognostic factors of mediastinal involvement, visceral involvement, and skin lesions, each with a relative risk of failure of about 2 7 . Atypical histological subtypes also may indicate a higher risk of relapse 2;8 . Despite the emergence of promising new treatment options for high-risk ALCL, such as allogeneic stem cell transplantation or monoclonal antibodies [9] [10] [11] , the paucity of identified risk factors prohibits defining a group of poor-risk patients for such interventions in first remission.
More than 80% of children and adolescents with ALCL carry the translocation t(2;5)(p23;q35) resulting in the specific fusion gene NPM-ALK [12] [13] [14] [15] [16] [17] . The fusion gene transcript can be readily and sensitively detected using reverse transcriptase PCR (RT-PCR) technology 18 , allowing not only a more accurate diagnosis of this lymphoma entity but also enabling detection of disease extension at a submicroscopic level. For personal use only. on . by guest www.bloodjournal.org From
Patients, materials, and methods

The studies NHL-BFM95 and ALCL99 were approved by the Justus-Liebig-University
IRB. Both IRB-approvals explicitly included the use of patient material for the study of new prognostic markers. All patients / their parents signed an informed consent to
use the material for the study of prognostic factors (in ALCL99 even more specified: minimal systemic disease).
Eligibility
Patients from study NHL-BFM95 with a diagnosis of ALCL and German patients enrolled in the European inter-group trial ALCL99 were potentially eligible for this study. Both studies were approved by the institutional Ethics committee of the primary investigator of the BFM group (A.R.). Eligibility was confirmed with demonstration of NPM-ALK positivity of the ALCL by either positive NPM-ALK PCR and/or positive two-color FISH for t(2;5) and/or nuclear and cytoplasmic staining for ALK in the tumor biopsy; in addition, bone marrow had to be available at diagnosis for PCR analyses. Immunohistochemical staining of ALK in both nucleus and cytoplasm is restricted to ALCL harboring the NPM-ALK fusion protein; all other known ALK fusion proteins are located exclusively in the cytoplasm 17 .
Histopathological diagnosis and ALK staining were confirmed using national reference pathology. Patients who had undergone significant steroid therapy for more than one week before diagnosis were excluded.
Patients
Between procedures included bone marrow aspiration cytology and spinal tap. Bone marrow biopsies were only done in less than 20% of patients. Bone marrow involvement was defined by morphologically detectable ALCL cells in the aspiration cytology, irrespective of numbers. All bone marrow smears were reviewed by two experienced hematologists at the NHL-BFM study center. The treatment strategy was based upon protocol NHL-BFM90, as described previously 4 . All patients except those with stage I/II-resected disease received six 5-day chemotherapy courses over a period of four to six months; those with stage I/II-resected disease received three. 10 patients from study ALCL99 were randomized to receive weekly vinblastine maintenance; the last patient finished this therapy in April 2005.
The median age of the 80 study patients at diagnosis was 12.8 years (range 1.1-17.9 years). The male-to-female ratio was 2.1 to 1. The clinical characteristics of the patients are shown in table I. There was no significant difference between the clinical characteristics of the 80 patients analyzed and the 143 German patients with an ALCL registered in the studies NHL-BFM95 and ALCL99 but not included in this study (supplementary table) . Central review by at least two experienced lymphoma pathologists according to the WHO classification led to the following distribution of histological subtypes: 39 common, 13 mixed, 14 lymphohistiocytic, 6 small cell, 1 giant cell, and 2 not further classified; two cases were diagnosed cytologically, and there was no more material available for the remaining three patients for subclassification. All cases were CD30 and ALK positive and were negative for the Bcell markers CD20 and CD79a. 39% expressed CD3.
Bone marrow (BM) was obtained from all patients before the start of therapy and send to the NHL-BFM study center within 24 hours. From 52 of the 80 study patients, peripheral blood (PB) could be evaluated for the presence of NPM-ALK- The PCR products were analyzed on an agarose gel and visualized by UV illumination after ethidium bromide staining.
Primers and probes
Real-time quantitative PCR (RQ-PCR) was performed using TaqMan technology. 
Standard plasmids and cell lines
Statistical analysis
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From Analysis of event-free survival (EFS) and survival was performed using the Kaplan-Meier method with differences compared by the log-rank test; standard error was calculated according to Greenwood [27] [28] [29] . EFS was calculated from the date of diagnosis to the first event (non-response, death from any cause, tumor progress, or second malignancy) or to the date of last follow-up, survival from the date of diagnosis to death from any cause, or last follow-up. Cumulative incidence functions for relapse were constructed following the method of Kalbfleisch and Prentice 30 .
Functions were compared with Gray's test 
Results
Sensitivity and specificity of the RT-PCR and RQ-PCR for NPM-ALK
The sensitivity and specificity of the RT-PCR was tested with Karpas299 NPM- 
Characteristics of patients with positive bone marrow PCR for NPM-ALK
The bone marrow (BM) was positive for the NPM-ALK transcript in 38 of the 80 patients (47.5%). The PCR result in BM significantly correlated with the clinical stage.
Only 2 of the 22 patients (9%) with stage I or II disease showed a positive PCR compared to 36 of the 58 patients (62%) with stage III or IV disease (P < .001, Table   1 ). There also was a significant association of a positive BM NPM-ALK PCR result with the known clinical risk features of involvement of mediastinum and visceral organs 7 ; the involvement of skin and CNS did not correlate with a positive RT-PCR ( The BM PCR result was not associated with the ALCL immunophenotype as defined by expression of the T-cell marker CD3, which was evaluated throughout the whole study period as part of the national reference pathology review. PB and BM varied slightly more than one log in 3 patients and more than 2 logs in 1 patient; NCN was higher in PB compared to BM in three of these four patients ( Figure   2 ).
Altogether, the comparison of both qualitative and quantitative PCR for NPM-ALK between BM and PB showed high concordance. However, more patients were positive in PB, and positive patients tended to have higher copy numbers in PB compared to BM.
Prognostic impact of a positive qualitative PCR for NPM-ALK in BM and PB
The median follow-up was 3.2 years. Only two patients had a follow-up of less than a year from diagnosis. Because relapse/progression occur early in pediatric ALCL, follow-up was sufficient to allow detailed analyses. Overall (OS) and eventfree survival (EFS) for the whole group of 80 patients analyzed by PCR were 74±6% and 61±6%, respectively. The cumulative incidence of relapse (CI-R) was 32±6%.
For
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The comparable data for EFS, CI-R and OS for the 143 German ALCL patients from trials NHL-BFM95 and ALCL99 but not included in this study were 72±4%, 25±4% and 90±3%, respectively. EFS and the CI-R of these 143 patients were statistically not significantly different from the 80 analyzed patients (p=0.12 for comparison of EFS and p=0.32 for comparison of CI-R), while OS was (p=0.02).
A total of 17 of the 38 patients with a positive BM PCR for NPM-ALK relapsed compared to 5 of the 42 patients with negative BM PCR (CI-R 50±10% versus 15±7%, P < .001) (Figure 3 ). Patients with a positive NPM-ALK PCR result in BM had an EFS and OS at five years of 38±9% and 60±9%, respectively, compared to 82±7% and 86±7%, respectively, for patients without detection of NPM-ALK in BM (P < .001 for EFS and .006 for OS).
The prognostic impact of the BM PCR depended on the stage of disease: Only 2 of 22 patients with stage I and II disease were BM PCR positive, and both remained free of disease. However, among the 58 patients with stage III or IV disease, 17 of 36 patients with positive PCR relapsed compared to 2 of 22 with negative BM PCR (cumulative incidence 54±11% versus 11.6±8%, P = .002).
Because of the high concordance of BM and PB PCR results in the 52 parallel patient samples, a positive PCR in PB also was associated with a high risk of failure.
Three of the 25 patients with negative PCR in PB relapsed compared to 10 of 27 patients with detection of NPM-ALK by PCR in PB (cumulative incidence 20±11% versus 41±11%, P = .03) resulting in a 5-year EFS of 46±10% and 80±11% for patients with and without positive PCR in PB, respectively (P = .004).
Only one of the seven patients with PCR results diverging between PB and BM relapsed; the patient was positive in PB. The three patients with relapse of a PB PCR-negative ALCL also were negative for NPM-ALK mRNA in BM, suggesting that application of PB in addition to BM does not enhance the negative predictive value of DOD, 1 TRM). However, relapse therapy for patients with progression during first-line therapy was more aggressive including allogeneic blood stem cell transplantation in most instances compared to patients with relapse after initial therapy. , be regarded as a reflection of circulating tumor cells rather than of true BM micrometastasis, which can often be detected in solid tumors.
Correlation of positive NPM-ALK PCR results in BM or PB with other prognostic factors
The relapse rate for patients with negative BM PCR still reached 15%, a risk comparable to that of patients without clinical risk features and with a common histological subtype 7 . In addition, those patients with positive BM PCR but less than 10 NCN NPM-ALK in the quantitative analysis have a similar low relapse rate than BM PCR-negative patients and could be added to this group. However, in contrast to the data of Mussolin et al. 19 , a very low risk group of patients amenable to therapy reduction could not be defined by measuring circulating tumor cells. In our cohort of patients, a group of about one-third of the patients with an EFS of 95% and an OS of 100% could only be identified by combining the positive factors of negative BM PCR and common histological subtype. But this finding has to be confirmed by a larger study.
Quantitative PCR in BM and PB, on the other hand, allowed identification of a poorer risk group of patients. While a positive qualitative PCR in BM and PB already conferred a 50% risk of relapse, the risk rose to 70% for patients with more than 10 NCN NPM-ALK in BM or PB. Methodological differences between this study and that with an Italian population might explain why the prognostic impact of a high tumor cell load measured by quantitative PCR in the current work could not be detected by the Italian group in bone marrow samples 19 . Tumor cells were enriched in the mononuclear cell fraction by density gradient centrifugation in our study, allowing a higher sensitivity than the measurement in nuclear cells (Damm-Welk et al., We do not have any competing financial interests to declare. 
